Characterization of gut microbiome and metabolome in <i>Helicobacter pylori</i> patients in an underprivileged community in the United States
Brian White, John Sterrett, Zoya Grigoryan, Lauren T. Lally, Jared D. Heinze, Hyder Alikhan, Christopher A. Lowry, Lark J. Perez, Joshua DeSipio, Sangita Phadtare
Abstract
BACKGROUND: , the fecal microbiome, and fecal fatty acid metabolism, as well as the mechanisms underlying these interactions, may offer new therapeutic approaches. AIM: patients in a socioeconomically challenged and underprivileged inner-city community. METHODS: gene sequencing was performed on normalized pooled amplicons using the Illumina MiSeq System using a MiSeq reagent kit v2. Alpha and beta diversity analyses were performed in QIIME 2. Non-targeted fatty acid analysis of the samples was carried out using gas chromatography-mass spectrometry, which measures the total content of 30 fatty acids in stool after conversion into their corresponding fatty acid methyl esters. Multi-dimensional scaling (MDS) was performed on Bray-Curtis distance matrices created from both the metabolomics and microbiome datasets and a Procrustes test was performed on the metabolomics and microbiome MDS coordinates. RESULTS: gene analysis. CONCLUSION: -associated changes to the fecal microbiome and fecal fatty acid metabolism. Such changes may have implications for improving eradication rates and minimizing associated negative distal outcomes.